Lars Fruergaard Jørgensen, Novo Nordisk CEO (EUBIO21)

No­vo Nordisk to make all dos­es of its weight loss drug avail­able in the US by end of the year

With pro­duc­tion fi­nal­ly up and run­ning for its weight loss drug We­govy, No­vo Nordisk said on Wednes­day that it plans to make all dose strengths …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.